EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder
The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
Exyn Technologies Partners with Measur to Expand Canadian Footprint
Measur plans to bring Exyn's cutting-edge technologies like the Nexys 3D SLAM LiDAR payload system to market.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Achieves FDA Clearance for Phase I Trial of its CAR T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iECURE Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
New Method Created for Improving the Resolution of Routine Medical Images
This novel method improves resolution of routine low resolution clinical images, saves MR scan time, and reduces radiation dosage levels for CT scanning.
Moderna Receives FDA Approval for RSV Vaccine Based on Penn Technology
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia.
Penn Arts and Sciences’ MindCORE Neuroimaging Facility at Pennovation Works
The machine is the centerpiece of the new Neuroimaging Facility where scientists will study the mind-brain connection in-depth.
Penn Engineering Researchers Develop New Technology that Transforms Reflective Displays
The invention consists of an array of individually addressable microscale optical resonators and arrangements of optical components which allow a beam of light to circulate more efficiently.
LNP Research from the Mitchell Lab is Highlighted in the Philadelphia Inquirer
Mike Mitchell, PhD, was interviewed recently by the Philadelphia Inquirer about his cutting-edge research in lipid nanoparticles (LNPs), which are crucial for delivering mRNA into the body's cells.